PCRX / Pacira BioSciences, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Pacira BioSciences Reports Second Quarter 2025 Financial Results -- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2025 Financial Results - Solid execution across corporate, clinical and commercial initiatives - - Several key milestones advance 5x30 path to growth - - Conference call today at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 PACIRA BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form type) PACIRA BIOSCIENCES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIO

As filed with the Securities and Exchange Commission on August 5, 2025

As filed with the Securities and Exchange Commission on August 5, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 PACIRA BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission F

On July 10, 2025, Pacira BioSciences, Inc. sent the following note to employees:

Exhibit 99.1 On July 10, 2025, Pacira BioSciences, Inc. sent the following note to employees: Subject: Organizational Update Please take a moment to read the note below, sent on behalf of Frank D. Lee ++++++++++++ Dear Colleagues, I want to share some important news regarding organizational changes at our Science Center Campus. After very careful consideration, we have made the decision to decommi

Credit agreement, dated as of July 3, 2025, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank.

Exhibit 10.1 Published CUSIP Number: [] Revolving Facility CUSIP Number: [] CREDIT AGREEMENT dated as of July 3, 2025 among PACIRA BIOSCIENCES, INC., as Borrower The Lenders Party Hereto WELLS FARGO BANK, NATIONAL ASSOCIATION as Administrative Agent, Swingline Lender and an Issuing Bank FIFTH THIRD BANK, NATIONAL ASSOCIATION, ROYAL BANK OF CANADA and U.S. BANK NATIONAL ASSOCIATION, as Documentatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 3, 2025 PACIRA BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 3, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Amended and Restated 2011 Stock Incentive Plan

Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN (As approved by stockholders on June 10, 2025) 1.Purpose The purpose of this Amended and Restated 2011 Stock Incentive Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, reta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BI

Pacira BioSciences Reports First Quarter 2025 Financial Results -- Conference call today at 4:30 p.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2025 Financial Results - Conference call today at 4:30 p.

SETTLEMENT AGREEMENT

Exhibit 10.1 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT (this “Agreement”) is made and effective as of April 7, 2025 (the “Effective Date”), by and among Pacira Bioscience

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2025 PACIRA BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL -- Fresenius Kabi licensed to sell volume-limited amounts of generic liposomal bupivacaine in the U.S. beginning on a confidential date in 2030 -- -- Fresenius also license

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL - Fresenius Kabi licensed to sell volume-limited amounts of generic liposomal bupivacaine in the U.S. beginning on a confidential date in 2030 - - Fresenius also licensed to sell generic liposomal bupivacaine in the U.S. without volume limitations no earlier than 2039 - Brisbane, CA, Ap

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

Third Amended and Restated Bylaws

Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF PACIRA BIOSCIENCES, INC. Adopted March 12, 2025 TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 4 1.11 Notice of Business at Annual Mee

INSIDER TRADING POLICY Updated December 2024

Exhibit 19 INSIDER TRADING POLICY Updated December 2024 1.BACKGROUND AND PURPOSE The federal securities laws prohibit any member of the Board of Directors (a “Director”), employee, or consultant of Pacira BioSciences, Inc. (together with its subsidiaries, the “Company”) from purchasing or selling securities of the Company or other companies on the basis of material nonpublic information concerning

SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a complete listing of the subsidiaries of Pacira BioSciences, Inc., a Delaware corporation: Jurisdiction of Incorporation Domestic Subsidiaries Pacira Pharmaceuticals, Inc. California Pacira CryoTech, Inc. Delaware Pacira Pharmaceuticals International, Inc. Delaware Pacira Therapeutics, Inc. Delaware International Subsidiaries GQ Bio The

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is entered into as of October 21, 2024 by and between Pacira Pharmaceuticals, Inc., a California corporation, any of its past, present, or future parents, subsidiaries, predecessors, affiliates, successors, officers, directors, assigns, investors, agents, owners, managing agents and insurers (the “C

AMENDMENT NO. 3 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT

Exhibit 10.39 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 3 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT This AMENDMENT NO. 3 (the "Third Amendment") to the TECHNICAL TRANSFER AND SERVICE AGREEMENT by and b

AMENDMENT NO. 5 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT

Exhibit 10.41 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 5 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT This AMENDMENT NO. 5 (the “Fifth Amendment”) to the TECHNICAL TRANSFER AND SERVICE AGREEMENT by and b

AMENDMENT NO. 2 TO MANUFACTURING AND SUPPLY AGREEMENT

EXHIBIT 10.35 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO MANUFACTURING AND SUPPLY AGREEMENT This AMENDMENT NO. 2 (the “Amendment”) to the MANUFACTURING AND SUPPLY AGREEMENT by and between Pacira Limi

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results — Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET —

NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results — Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

SPECIMEN CERTIFICATE EVIDENCING SHARES OF COMMON STOCK PACIRA BIOSCIENCES, INC.

Exhibit 4.1 SPECIMEN CERTIFICATE EVIDENCING SHARES OF COMMON STOCK PACIRA BIOSCIENCES, INC.

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form type) PACIRA BIOSCIENCES, INC.

AMENDMENT NO. 1 TO MANUFACTURING AND SUPPLY AGREEMENT

Exhibit 10.34 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO MANUFACTURING AND SUPPLY AGREEMENT This AMENDMENT NO. 1 (the "First Amendment") to the MANUFACTURING AND SUPPLY AGREEMENT by and between Pacir

AMENDMENT NO. 2 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT

Exhibit 10.38 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT This AMENDMENT NO. 2 (the “Second Amendment”) to the TECHNICAL TRANSFER AND SERVICE AGREEMENT by and

AMENDMENT NO. TWO TO PACIRA BIOSCIENCES, INC. DEFERRED COMPENSATION PLAN

Exhibit 10.30 AMENDMENT NO. TWO TO PACIRA BIOSCIENCES, INC. DEFERRED COMPENSATION PLAN This Amendment No. Two is made to the Pacira BioSciences, Inc. Deferred Compensation Plan (the "Plan"). The amendment set forth herein is effective as of January 1, 2025. All terms defined in the Plan shall have the same meanings when used herein. All provisions of the Plan not amended by this Amendment No. One

AMENDMENT NO. 4 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT

Exhibit 10.40 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 4 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT This AMENDMENT NO. 4 (the "Fourth Amendment") to the TECHNICAL TRANSFER AND SERVICE AGREEMENT by and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2024 Or ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3

As filed with the Securities and Exchange Commission on February 27, 2025

As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.

PACIRA BIOSCIENCES, INC. LONG-TERM INCENTIVE PLAN

Exhibit 10.31 PACIRA BIOSCIENCES, INC. LONG-TERM INCENTIVE PLAN 1. Purpose. Pacira BioSciences, Inc. (the “Company”) has established this Long-Term Incentive Plan (“LTIP”) to reward officers and selected key employees of the Company or any of its subsidiaries for their contributions to the long-term performance of the Company. The LTIP is a cash-based plan that rewards effective use of the Company

AMENDMENT NO. 1 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT

Exhibit 10.37 AMENDMENT NO. 1 TO TECHNICAL TRANSFER AND SERVICE AGREEMENT This AMENDMENT NO. 1 (the “Amendment”) to the TECHNICAL TRANSFER AND SERVICE AGREEMENT by and between Pacira Pharmaceuticals, Inc., a California corporation having its principal place of business at 5 Sylvan Way, Parsippany, NJ 07054, United States (“Pacira”), and Patheon UK Limited, a company incorporated in England and Wal

Pacira Announces Updates to Board of Directors -- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Announces Updates to Board of Directors - Accomplished Business and Financial Leader, Laura Brege, Appointed Chair - - Paul J.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2025 PACIRA BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

Form of Nonstatutory Stock Option Agreement under the Amended and Restated 2014 Inducement Plan

Exhibit 10.2 PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2014 Inducement Plan 1.Grant of Option. This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the “Company”), on [GRANT DATE] (the “Grant Date”) to [PARTICIPANT NAME], (the “Participant”), of an option to purchase, in whole or in part, on the terms provided

Amended and Restated 2014 Inducement Plan

Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 INDUCEMENT PLAN 1. Purpose The purpose of this Amended and Restated 2014 Inducement Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expected to make important contributions to t

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments -- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to support company’s 5x30 path to becoming

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments - Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer - - Key additions expected to support company’s 5x30 path to becoming an innovative biopharmaceutical organization - Parsippany, NJ, Jan.

Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Inducement Plan

Exhibit 10.3 PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2014 INDUCEMENT PLAN Pacira BioSciences, Inc. (the "Company") hereby grants to Participant a Restricted Stock Unit Award (the "Award"). The Award is subject to all the terms and conditions set forth in this Restricted Stock Unit Award Notice (the "Award Notice") and in the Restricted Stock Unit Award Agre

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 16, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

JOINT FILING AGREEMENT

EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization -- Company also reports preliminary unaudited 2024 revenue of $701.0 million --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization - Company also reports preliminary unaudited 2024 revenue of $701.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2025 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

NON-HEALTHCARE PROFESSIONAL CONSULTING AGREEMENT

Exhibit 10.5 NON-HEALTHCARE PROFESSIONAL CONSULTING AGREEMENT Effective Date: October 1, 2024 Expiration Date: June 30, 2025 This Non-Healthcare Professional Consulting Agreement (the “Agreement”) is entered into by and between Pacira Pharmaceuticals, Inc., a California corporation, having a place of business at 5 Sylvan Way, Parsippany, New Jersey 07054 (“Pacira”), (hereinafter “Pacira”), and Cha

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

, 2024 , by and between Pacira Pharmaceuticals, Inc. and Daryl Gaugler.

Exhibit 10.1 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment No. 1 to Executive Employment Agreement (this “Amendment”), is entered into as of October 31, 2024, by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Daryl Gaugler (the “Executive”) (collectively, the “Parties”). RECITALS WHEREAS, the Company is a wholly-owned subsidiary of Pacira

AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT

Exhibit 10.4 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT This Amendment No. 3 to Employment Agreement (this “Amendment”), is entered into as of August 16, 2024, by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Lauren Riker (the “Employee”) (collectively, the “Parties”). RECITALS WHEREAS, the Company is a wholly-owned subsidiary of Pacira BioSciences, Inc., a D

Amended and Restated Executive Employment Agreement, dated as of November 4, 2024, by and between Pacira Pharmaceuticals, Inc. and Lauren Riker.

Exhibit 10.4 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”), is entered into as of November 4, 2024, by and between Pacira Pharmaceuticals, Inc., a California corporation, any of its past, present, or future parents, subsidiaries, predecessors, affiliates, successors, officers, directors, assigns, investors, agents, ow

, 2024, by and between Pacira Pharmaceuticals, Inc. and Jonathan Slonin.

Exhibit 10.2 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment No. 1 to Executive Employment Agreement (this “Amendment”), is entered into as of October 31, 2024, by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Jonathan Slonin (the “Executive”) (collectively, the “Parties”). RECITALS WHEREAS, the Company is a wholly-owned subsidiary of Paci

PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 INDUCEMENT PLAN

Exhibit 10.6 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 INDUCEMENT PLAN 1. Purpose The purpose of this Amended and Restated 2014 Inducement Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expected to make important contributions to t

PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2014 INDUCEMENT PLAN

Exhibit 10.8 PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2014 INDUCEMENT PLAN Pacira BioSciences, Inc. (the "Company") hereby grants to Participant a Restricted Stock Unit Award (the "Award"). The Award is subject to all the terms and conditions set forth in this Restricted Stock Unit Award Notice (the "Award Notice") and in the Restricted Stock Unit Award Agre

Pacira BioSciences Reports Third Quarter 2024 Financial Results -- Conference call today at 4:30 p.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2024 Financial Results - Conference call today at 4:30 p.

, 2024, by and between Pacira Pharmaceuticals, Inc. and Kristen Williams.

Exhibit 10.3 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT This Amendment No. 3 to Employment Agreement (this “Amendment”), is entered into as of October 31, 2024, by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Kristen Williams (the “Employee”) (collectively, the “Parties”). RECITALS WHEREAS, the Company is a wholly-owned subsidiary of Pacira BioSciences, Inc.

AMENDMENT NO. 2 TO EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.3 AMENDMENT NO. 2 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment No. 2 to Executive Employment Agreement (this “Amendment”), is entered into as of June 30, 2015, by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”) and Lauren Riker (“Executive”). RECITALS A. The parties desire to amend the Executive Employment Agreement, dated April 19, 2012 by and bet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIR

PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2014 Inducement Plan

Exhibit 10.7 PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2014 Inducement Plan 1.Grant of Option. This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the “Company”), on [GRANT DATE] (the “Grant Date”) to [PARTICIPANT NAME], (the “Participant”), of an option to purchase, in whole or in part, on the terms provided

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 16, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, FL, October 21, 2024 - Pacira BioSciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 26, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 3, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2024 PACIRA BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.

Pacira BioSciences Reports Second Quarter 2024 Financial Results -- Conference call today at 4:30 p.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2024 Financial Results - Conference call today at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

FIFTH AMENDMENT TO CONSULTING AGREEMENT

Exhibit 10.3 FIFTH AMENDMENT TO CONSULTING AGREEMENT This Amendment (this “Amendment”) to the Consulting Agreement dated June 2, 2011, as restated and amended, (the “Consulting Agreement”) by and between Pacira Pharmaceuticals, Inc. (“Pacira”) and Gary Pace, Ph.D. (the “Consultant”) (together, the “Parties”) is made effective as of June 12, 2024 (“Amendment Effective Date”) with respect to the fol

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

Exhibit 99.1 Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 May 10, 2024 TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) - Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualifi

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction (Commission (IRS Employer of inc

Form of Capped Call Transaction Confirmation

Exhibit 10.1 [Insert Dealer Address] [], 2024 To: Pacira BioSciences, Inc. [] [] Attention: [Title of contact] Telephone No.: [] Facsimile No.: [] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer] (“Dealer”) and Pacira BioSciences, Inc., a Dela

Indenture, dated as of May 14, 2024, by and between the Company and Computershare Trust Company, National Association.

  Exhibit 4.1   EXECUTION VERSION       PACIRA BIOSCIENCES, INC.   and   COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee   INDENTURE   Dated as of May 14, 2024   2.125% Convertible Senior Notes due 2029             TABLE OF CONTENTS   Page     Article 1     Definitions         Section 1.01 Definitions 1 Section 1.02 Rules of Construction 12         Article 2     Issue, Description, E

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

Exhibit 99.1 Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes May 8, 2024 TAMPA, Fla., May 8, 2024 - Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a pr

First Amendment, dated as of May 8, 2024, to Credit Agreement, dated as of March 31, 2023, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of May 8, 2024, is made by and among PACIRA BIOSCIENCES, INC., a Delaware corporation (the “Borrower”), each Subsidiary Guarantor, each Lender (as defined below) party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent to the Lenders (the “Administrati

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction (Commission (IRS Employer of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BI

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program -- Conference call today at 4:30 p.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program - Conference call today at 4:30 p.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.         )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.         ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

SPECIMEN CERTIFICATE EVIDENCING SHARES OF COMMON STOCK PACIRA BIOSCIENCES, INC.

Exhibit 4.1 SPECIMEN CERTIFICATE EVIDENCING SHARES OF COMMON STOCK PACIRA BIOSCIENCES, INC. Exhibit 4.1

PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2014 Inducement Plan

Exhibit 10.8 PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2014 Inducement Plan 1.Grant of Option. This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the “Company”), on [GRANT DATE] (the “Grant Date”) to [PARTICIPANT NAME], (the “Participant”), of an option to purchase, in whole or in part, on the terms provided

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN

Exhibit 10.6 Non-Employee Directors PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN Pacira BioSciences, Inc. (the "Company") hereby grants to Participant a Restricted Stock Unit Award (the "Award"). The Award is subject to all the terms and conditions set forth in this Restricted Stock Unit Award Notice (the "Award Notice") and in the Rest

AMENDMENT AGREEMENT

Exhibit 10.32 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT AGREEMENT First Amendment to the Manufacturing and Supply Agreement This Amendment Agreement (this “Amendment Agreement”) is between Flexion Therapeuti

PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2014 INDUCEMENT PLAN

Exhibit 10.9 PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2014 INDUCEMENT PLAN Pacira BioSciences, Inc. (the "Company") hereby grants to Participant a Restricted Stock Unit Award (the "Award"). The Award is subject to all the terms and conditions set forth in this Restricted Stock Unit Award Notice (the "Award Notice") and in the Restricted Stock Unit Award Agre

AMENDMENT AGREEMENT

Exhibit 10.33 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT AGREEMENT Second Amendment to the Manufacturing and Supply Agreement This Amendment Agreement (this “Amendment Agreement”) is between Flexion Therapeut

PACIRA BIOSCIENCES, INC. INDEMNIFICATION AGREEMENT

Exhibit 10.22 PACIRA BIOSCIENCES, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement made and entered into this day of , 20 (the “Agreement”), by and between Pacira BioSciences, Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company) and (the “Indemnitee”): WHEREAS, it

COMMERCIAL OUTSOURCING SERVICES AGREEMENT

Exhibit 10.23 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL OUTSOURCING SERVICES AGREEMENT This Commercial Outsourcing Services Agreement (this “Agreement”) is entered into as of February 26, 2024 (the “Effecti

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form type) PACIRA BIOSCIENCES, INC.

PACIRA BIOSCIENCES, INC. Incentive Compensation Recovery Policy

Exhibit 97 PACIRA BIOSCIENCES, INC. Incentive Compensation Recovery Policy 1.Purpose The purpose of the Pacira BioSciences, Inc. Incentive Compensation Recovery Policy (this “Policy”) is to provide for the recovery of certain Incentive-Based Compensation in the event of an Accounting Restatement. This Policy is intended to comply with, and to be administered and interpreted consistent with, Sectio

PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN

Exhibit 10.5 PACIRA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD NOTICE AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN Pacira BioSciences, Inc. (the "Company") hereby grants to Participant a Restricted Stock Unit Award (the "Award"). The Award is subject to all the terms and conditions set forth in this Restricted Stock Unit Award Notice (the "Award Notice") and in the Restricted Stock Unit Award

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mar

NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.

SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a complete listing of the subsidiaries of Pacira BioSciences, Inc., a Delaware corporation: Jurisdiction of Incorporation Domestic Subsidiaries Pacira Pharmaceuticals, Inc. California Pacira CryoTech, Inc. Delaware Pacira Therapeutics, Inc. Delaware Pacira Pharmaceuticals International, Inc. Delaware International Subsidiaries Pacira Lim

AMENDMENT AGREEMENT Third Amendment to the Manufacturing and Supply Agreement

Exhibit 10.34 PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT AGREEMENT Third Amendment to the Manufacturing and Supply Agreement This Amendment Agreement (this “Amendment Agreement”) is between Pacira Pharmaceuti

As filed with the Securities and Exchange Commission on February 29, 2024

As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 Or ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3

PCRX / Pacira BioSciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01646-pacirabiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Pacira BioSciences Inc Title of Class of Securities: Common Stock CUSIP Number: 695127100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 4, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissio

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues TAMPA, Fla.

Executive Employment Agreement, dated December 20, 2023, by and between Pacira Pharmaceuticals, Inc. and Frank Lee.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is entered into as of December 20, 2023, by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Frank Lee (the “Executive”) (collectively the “Parties”). RECITALS WHEREAS, the Company wishes to employ the Executive, and the Executive desires to be employed by the C

Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan.

Exhibit 10.2 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 INDUCEMENT PLAN 1. Purpose The purpose of this Amended and Restated 2014 Inducement Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expected to make important contributions to t

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

Pacira Appoints Frank D. Lee as Chief Executive Officer -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Appoints Frank D. Lee as Chief Executive Officer - Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization - - Paul J. Hastings Named Chair of the Board - - Dave Stack to Remain in Advisory Role through August 2025 - TAMPA, Fla., December 21, 2023 (GLOBE NEWSWIRE) - Pac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIR

Pacira BioSciences Reports Third Quarter 2023 Financial Results -- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 202

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2023 Financial Results - New ASA initiatives to advance education and innovation for the anesthesia community - - PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 - - Conference call today at 8:30 a.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors -- Enhances diversity and expertise in key areas including scientific, commercial, and financial --

Exhibit 99.1 FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors - Enhances diversity and expertise in key areas including scientific, commercial, and financial - TAMPA, FL, October 10, 2023 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health soluti

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissio

* * * *

October 6, 2023 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 20, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commis

TRANSITION AND RETIREMENT AGREEMENT

Exhibit 10.1 TRANSITION AND RETIREMENT AGREEMENT This TRANSITION AND RETIREMENT AGREEMENT (this “Agreement”) is entered into as of September 20, 2023 (the “Effective Date”) by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company,” which term shall include any of the Company’s parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue

Pacira BioSciences Announces Leadership Succession Plan David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor

Exhibit 99.1 FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Announces Leadership Succession Plan David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla, September 26, 2023 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2023 PACIRA BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIO

CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLA

Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. June 5, 2023 Patheon UK Limited Executive Director & General Manager Kingfisher Drive, Covingham

Pacira BioSciences Reports Second Quarter 2023 Financial Results -- Conference call today at 8:30 a.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2023 Financial Results - Conference call today at 8:30 a.

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form type) PACIRA BIOSCIENCES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2023 PACIRA BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

As filed with the Securities and Exchange Commission on August 2, 2023

As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.

Amended and Restated 2011 Stock Incentive Plan

Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN (As approved by stockholders on June 13, 2023) 1.Purpose The purpose of this Amended and Restated 2011 Stock Incentive Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, reta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 PACIRA BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Reports First Quarter 2023 Financial Results -- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2023 Financial Results - EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year - - Conference call today at 8:30 a.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission Fi

EXECUTIVE EMPLOYMENT AGREEMENT

EX-10.1 2 exhibit101-3312023xpcrx.htm EX-10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is entered into as of June 17, 2019 (the “Effective Date”), by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Daryl Gaugler (the “Executive”). RECITALS WHEREAS, the Company wishes to employ the Executive, and the E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BI

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is entered into as of December 6, 2016 (the “Effective Date”), by and between Pacira Pharmaceuticals, Inc., a California corporation (the “Company”), and Anthony Molloy (the “Executive”). RECITALS WHEREAS, the Company wishes to employ the Executive, and the Executive desires to be employed by the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Credit agreement, dated as of March 31, 2023, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of March 31, 2023 among PACIRA BIOSCIENCES, INC. as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent and JPMORGAN CHASE BANK, N.A., as Bookrunner and Lead Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 1 Section 1.01. Defined Terms 1 Section 1.02. Classification of Loans and Borrowings 43 Section 1.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2023 PACIRA BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources – Term Loan A Carries Significantly Lower Interest Rate – – Meaningfully Impro

Exhibit 99.1 FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources – Term Loan A Carries Significantly Lower Interest Rate – – Meaningfully Improves Debt Leverage Ratio and Reaffirms Outlook for Growth – TAMPA, FL, April 3, 2023 - Pacira BioScienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 18, 2023 PACIRA BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 18, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Announces Departure of Yvonne Greenstreet from Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Announces Departure of Yvonne Greenstreet from Board of Directors TAMPA, FL, March 22, 2023 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that after serving as an independent director for nine years, Yvonne Greenstree

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 Or ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3

SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a complete listing of the subsidiaries of Pacira BioSciences, Inc., a Delaware corporation: Jurisdiction of Incorporation Domestic Subsidiaries Pacira Pharmaceuticals, Inc. California Pacira CryoTech, Inc. Delaware Pacira Therapeutics, Inc. Delaware Pacira Pharmaceuticals International, Inc. Delaware International Subsidiaries Pacira Lim

AMENDMENT NO. ONE TO PACIRA BIOSCIENCES, INC. DEFERRED COMPENSATION PLAN

Exhibit 10.25 AMENDMENT NO. ONE TO PACIRA BIOSCIENCES, INC. DEFERRED COMPENSATION PLAN This Amendment No. One is made to the Pacira BioSciences, Inc. Deferred Compensation Plan (the “Plan”). The amendment set forth herein is effective as of January 1, 2023. All terms defined in the Plan shall have the same meanings when used herein. All provisions of the Plan not amended by this Amendment No. One

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results — Record revenues of $667 million in 2022 — — Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million — — EXPAREL surpasses the 12 million patient mar

NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results — Record revenues of $667 million in 2022 — — Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million — — EXPAREL surpasses the 12 million patient mark — — Conference call today at 8:30 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2023 PACIRA BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

Page 13 of 13

EX-99.B 3 d443025dex99b.htm EX-99.B Exhibit 99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021. Page 13 of 13

PCRX / Pacira Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment

SC 13G/A 1 d443025dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Pacira Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 695127100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

Page 9 of 13

EX-99.A 2 d443025dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). WHEREAS, th

PCRX / Pacira Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01616-pacirabiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Pacira BioSciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 695127100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissio

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million -- EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2022 PACIRA BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022 -- EXPAREL sales were 99 percent and unit volumes were 104 percent of November 2021 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $57.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 PACIRA BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022 -- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $54.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 PACIRA BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

Pacira BioSciences Reports Third Quarter 2022 Financial Results -- Third quarter revenue of $167 million, increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2022 Financial Results - Third quarter revenue of $167 million, increased 31% over prior year - - Conference call today at 8:30 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 13, 2022 PACIRA BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 13, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million -- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 13, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commis

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022 -- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $59.

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022 -- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $50.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form type) PACIRA BIOSCIENCES, INC.

As filed with the Securities and Exchange Commission on August 4, 2022

As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Reports Second Quarter 2022 Financial Results -- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition -- -- Strong topline performance de

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2022 Financial Results - Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition - - Strong topline performance delivers solid net income and significantly positive adjusted EBITDA - - Conference call today at 8:30 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 14, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million -- EXPAREL average daily sales at 105% of the prior year for the second quarter and 103% of the prior year for the month of June --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022 – EXPAREL average daily sales for May 2022 were 104 percent of May 2021 –

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera? of $46.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 7, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission F

Amended and Restated 2014 Employee Stock Purchase Plan.

Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN (As approved by stockholders on June 7, 2022) SECTION 1. PURPOSE The purposes of the Amended and Restated 2014 Employee Stock Purchase Plan (the ?Plan?) are to (a) assist qualified employees of the Company, and its Designated Subsidiaries in acquiring a stock ownership interest in the Company and (b) encou

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission F

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022 – EXPAREL average daily sales for April 2022 were 109 percent of April 2021 –

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera? of $45.

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?), is entered into as of May 4, 2020 (the ?Effective Date?), by and between Pacira Pharmaceuticals, Inc., a California corporation (the ?Company?), and Jonathan Slonin (the ?Executive?). RECITALS WHEREAS, the Company wishes to employ the Executive, and the Executive desires to be employed by the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BI

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission Fi

Pacira BioSciences Reports First Quarter 2022 Financial Results -- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call tod

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2022 Financial Results - First quarter revenue of $158 million, up 33% over prior year - - Strong topline performance delivers net income and significantly positive adjusted EBITDA - - Conference call today at 8:30 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION? Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022 – EXPAREL achieved record net product sales of $51.2 million for month of March with average daily sales at 116% of the prior year –

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Revenues of $157.

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022 -- EXPAREL average daily sales for February 2022 were 117% of February 2021 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera? of $42.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission

TECHNICAL TRANSFER AND SERVICE AGREEMENT

Exhibit 10.37 TECHNICAL TRANSFER AND SERVICE AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. TECHNICAL TRANSFER AND SERVICE AGREEMENT This TECHNICAL TRANSFER AND SERVICE AGREEMENT (this ?Agreement?), dated as of July 31, 2015 (the ?Effective Date?), is made by and betwe

FLEXION THERAPEUTICS, INC. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Dated as of May 2, 2017 3.375% Convertible Senior Notes due 2024 TABLE OF CONTENTS

Exhibit 4.4 EXECUTION VERSION FLEXION THERAPEUTICS, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 2, 2017 3.375% Convertible Senior Notes due 2024 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designatio

FLEXION THERAPEUTICS, INC. WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of November 19, 2021 3.375% Convertible Senior Notes due 2024

Exhibit 4.5 FLEXION THERAPEUTICS, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of November 19, 2021 3.375% Convertible Senior Notes due 2024 FIRST SUPPLEMENTAL INDENTURE, dated as of November 19, 2021 (this ?Supplemental Indenture?), between Flexion Therapeutics, Inc., a Delaware corporation (the ?Company?), as issuer, and Wells Fargo Bank, Nati

PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement for Non-Employee Directors Granted Under Amended and Restated 2011 Stock Incentive Plan

Exhibit 10.4 PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement for Non-Employee Directors Granted Under Amended and Restated 2011 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the ?Company?), on [GRANT DATE] (the ?Grant Date?) to [PARTICIPANT NAME], (the ?Participant?), of an option to purchase, in whole

CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLA

Exhibit 10.38 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK ?[***]?. April 8, 2020 VIA ELECTRONIC MAIL Patheon UK Ltd Executive Director & General Manager Kingfishe

MANUFACTURING AND SUPPLY AGREEMENT

EXHIBIT 10.36 MANUFACTURING AND SUPPLY AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. MANUFACTURING AND SUPPLY AGREEMENT This MANUFACTURING AND SUPPLY AGREEMENT (this ?Agreement?) dated as of July 31, 2015 (the ?Effective Date?) is made by and between Flexion Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2021 ☐ TRANSITION REPORT PURSU

Table of Contents, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2011 Stock Incentive Plan

Exhibit 10.3 PACIRA BIOSCIENCES, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2011 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the ?Company?), on [GRANT DATE] (the ?Grant Date?) to [PARTICIPANT NAME], (the ?Participant?), of an option to purchase, in whole or in part, on the terms pr

SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a listing of the subsidiaries of Pacira BioSciences, Inc., a Delaware corporation: Jurisdiction of Incorporation Domestic Subsidiaries Pacira Pharmaceuticals, Inc. California Pacira CryoTech, Inc. Delaware Pacira Pharmaceuticals International, Inc. Delaware Pacira Therapeutics, Inc. Delaware Flexion Therapeutics Securities Corporation Ma

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results — Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million

NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results ? Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 ? ? Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million ? ? More than 10 million patients have received EXPAREL since launch ? ? Conference call today at 8:30 a.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commiss

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022 -- EXPAREL average daily sales for January 2022 were 104% of January 2021 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.

PCRX / Pacira Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Pacira Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 695127100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

PCRX / Pacira Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Pacira BioSciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 695127100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file

PACIRA BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.3 PACIRA BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On November 19, 2021, Pacira BioSciences, Inc. (?Pacira? or the ?Company?) completed the acquisition (the ?Acquisition?) of Flexion Therapeutics, Inc. (?Flexion?), pursuant to an Agreement and Plan of Merger, dated October 11, 2021, by and among Pacira, Oyster Acquisition Company Inc., a Delaware corp

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of inc

Pacira Reports Preliminary Unaudited Total Revenue for 2021 of of $540.7 Million to $541.7 Million -- EXPAREL achieves record net product sales of $506.5 million for the full-year, $139.9 million for the fourth quarter, and $50.9 million for the mont

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Reports Preliminary Unaudited Total Revenue for 2021 of of $540.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2022 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissio

Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B -- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow --

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B - Provides additional operational and financial flexibility - - Underscores strength of forecasted earnings and operating cash flow - TAMPA, FL, December 9, 2021 ? Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and

Credit Agreement, dated as of December 7, 2021, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of December 7, 2021 among PACIRA BIOSCIENCES, INC. as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent and JPMORGAN CHASE BANK, N.A., as Bookrunner and Lead Arranger and SILVER POINT FINANCE, LLC, as Syndication Agent TABLE OF CONTENTS Page ARTICLE I Definitions 1 Section 1.01. Defined Terms 1 Section 1.02.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction (Commission File Number) (I

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021 -- EXPAREL average daily sales for November 2021 - 122% of November 2020 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL? and iovera? of $48.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 7, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) FLEXION THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Oyster Acquisition Company Inc. (Offeror) a wholly owned subsidiary of PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Person

Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opi

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management - Adds highly complementary ZILRETTA? to Pacira commercial offering - - Combined portfolio offers end-to-end non-opioid solutions along the pain pathway - TAMPA, FL and BURLINGTON, MA, November 19, 2021 ? Pacira BioScienc

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction (Commission File Number) (

Press Release issued by Pacira BioSciences, Inc. on November 19, 2021.

Exhibit (a)(5)(D) NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management - Adds highly complementary ZILRETTA? to Pacira commercial offering - - Combined portfolio offers end-to-end non-opioid solutions along the pain pathway - TAMPA, FL and BURLINGTON, MA, November 19, 2021 ? Pacira BioSciences, Inc.

Contingent Value Right Agreement, dated as of November 19, 2021, by and between Pacira BioSciences, Inc. and American Stock Transfer & Trust Company, LLC.

Exhibit 10.1 CONTINGENT VALUE RIGHT AGREEMENT This Contingent Value Right Agreement, dated as of November 19, 2021 (this ?Agreement?), is entered into by and between Pacira BioSciences, Inc., a Delaware corporation (?Parent?), and American Stock Transfer & Trust Company, LLC, a New York limited liability company, as Rights Agent (the ?Rights Agent?). RECITALS WHEREAS, Parent, Oyster Acquisition Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) FLEXION THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Oyster Acquisition Company Inc. (Offeror) a wholly owned subsidiary of PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Person

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) FLEXION THERAPEUTICS, INC. (Name of Subject Company

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ? FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) ? OYSTER ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of F

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021 -- EXPAREL average daily sales for October 2021 were 109% of October 2020 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $44.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIR

Pacira BioSciences Reports Third Quarter 2021 Financial Results -- Third quarter GAAP net income of $17.7 million and adjusted EBITDA of $48.1 million -- -- Conference call today at 8:30 a.m. ET --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2021 Financial Results - Third quarter GAAP net income of $17.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) FLEXION THERAPEUTICS, INC. (Name of Subject Company

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ? FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) ? OYSTER ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of F

Form of Letter to Clients for use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

?? ?Exhibit (a)(1)(E)? Offer to Purchase for Cash All Outstanding Shares of Common Stock of Flexion Therapeutics, Inc.

Form of Notice of Guaranteed Delivery.*

?? ?Exhibit (a)(1)(C)? Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of Flexion Therapeutics, Inc.

Offer to Purchase dated October 22, 2021.*

TABLE OF CONTENTS? ?Exhibit (a)(1)(A)? Offer to Purchase for Cash All Outstanding Shares of Common Stock of Flexion Therapeutics, Inc.

Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

?? ?Exhibit (a)(1)(D)? Offer to Purchase for Cash All Outstanding Shares of Common Stock of Flexion Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) OYSTER

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ? FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) ? OYSTER ACQUISITION COMPANY INC. (Offeror) a wholly owned subsidiary of PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) ? C

Confidentiality Agreement, dated as of June 1, 2021, by and between Pacira BioSciences, Inc. and Flexion Therapeutics, Inc.*

Exhibit (d)(4) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (?Agreement?) is being entered into as of June 1, 2021, between Flexion Therapeutics, Inc.

Exclusivity Agreement, dated as of September 25, 2021, by and between Pacira BioSciences, Inc. and Flexion Therapeutics, Inc.*

Exhibit (d)(5) EXCLUSIVITY AGREEMENT This Exclusivity Agreement (this ?Agreement?) is made as of September 25, 2021, between Pacira BioSciences, Inc.

Summary Newspaper Advertisement, as published in

Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

Form of Letter of Transmittal (including Internal Revenue SeArvice Form W-9).*

?? ?Exhibit (a)(1)(B)? Letter of Transmittal to Tender Shares of Common Stock of Flexion Therapeutics, Inc.

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solution

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management - Adds highly complementary ZILRETTA? to Pacira commercial offering - - Combined portfolio offers end-to-end non-opioid solutions along the pain pathway - - Further enhances topline revenue growth; provides attractive potential syner

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction (Commission File Number) (I

Agreement and Plan of Merger, dated as of October 11, 2021, by and among Pacira BioSciences, Inc., Oyster Acquisition Company Inc. and Flexion Therapeutics, Inc., incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Pacira BioSciences, Inc. on October 12, 2021.

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: FLEXION THERAPEUTICS, INC., PACIRA BIOSCIENCES, INC., and OYSTER ACQUISITION COMPANY INC. Dated as of October 11, 2021 TABLE OF CONTENTS Page Article 1 DEFINITIONS 2 Section 1.1 Definitions 2 Article 2 THE OFFER 15 Section 2.1 The Offer 15 Section 2.2 Company Actions 18 Article 3 MERGER TRANSACTION 19 Section 3.1 Merger of Pu

Form of Tender and Support Agreement, dated as of October 11, 2021, incorporated by reference to Exhibit 10.1 to the Current Report Form 8-K filed by Pacira BioSciences, Inc. on October 12, 2021.

Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this ?Agreement?) is entered into as of October 11, 2021, by and among Pacira BioSciences, Inc., a Delaware corporation (?Parent?), Oyster Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent (?Purchaser?), and [?] (?Stockholder?). Recitals A. Stockholder is a holder of record and the ?

Pacira BioSciences October 11, 2021

Exhibit 99.3 Pacira BioSciences October 11, 2021 Corporate Speakers: ? Susan Mesco; Pacira BioSciences, Inc.; Head of IR ? David Stack; Pacira BioSciences, Inc.; Chairman & CEO ? Ronald Ellis; Pacira BioSciences, Inc.; SVP ? Charles Reinhart; Pacira BioSciences, Inc.; CFO Participants: ? David Amsellem; Piper Sandler & Co.; Research Division, MD & Senior Research Analyst ? David Steinberg; Jefferi

Please take a moment to read the following communication, being sent on behalf of Dave Stack

Exhibit 99.4 Please take a moment to read the following communication, being sent on behalf of Dave Stack Dear [XXX], It is my pleasure to share with you that Pacira has announced a definitive agreement to acquire Flexion Therapeutics, a commercial-stage biopharmaceutical company focused on the development of novel, local non-opioid therapies for the treatment of patients with musculoskeletal cond

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 PACIRA BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction (Commission File Number) (I

Pacira to Acquire Flexion, Further Expanding Leadership Position in Non-Opioid Pain Management October 11, 2021 Forward-looking statements and where to find additional information 2 Any statements in this communication about Pacira BioSciences, Inc.’

Exhibit 99.2 Pacira to Acquire Flexion, Further Expanding Leadership Position in Non-Opioid Pain Management October 11, 2021 Forward-looking statements and where to find additional information 2 Any statements in this communication about Pacira BioSciences, Inc.?s (?Pacira?) or Flexion Therapeutics, Inc.?s (?Flexion?) future expectations, plans, trends, outlook, projections and prospects, and othe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commis

Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021 -- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EX

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $42.

Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021 -- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 --

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Preliminary Net Product Sales of $42.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2021 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commissio